HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients

Journal of Immunology

Volumn 185, Issue 12, 2010, Pages 7452-7459

  De Kruijf, Esther M ^a   Sajet, Anita ^a   Van Nes, Johanna G H ^a   Natanov, Russ ^a   Putter, Hein ^a   Smit, Vincent T H B M ^a   Liefers, Gerrit Jan ^a   Van Den Elsen, Peter J ^b,c   Van De Velde, Cornelis J H ^a   Kuppen, Peter J K ^a  

^a Department of Surgery ^*  (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HLA E ANTIGEN; HLA G ANTIGEN; PROGESTERONE RECEPTOR;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; BREAST SURGERY; BREAST TUMOR; CANCER PATIENT; CANCER RELAPSE; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; DISEASE FREE INTERVAL; DOWN REGULATION; EARLY CANCER; GENE LOCUS; HLA SYSTEM; HUMAN; HUMAN TISSUE; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; IMMUNOSURVEILLANCE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; TISSUE MICROARRAY; TUMOR CLASSIFICATION; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 78650666422     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1002629     Document Type: Article

References (39)

1. Van Pel, A., and T. Boon. 1982. Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. Proc. Natl. Acad. Sci. USA 79:4718-4722.
2. Khong, H. T., and N. P. Restifo. 2002. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat. Immunol. 3:999-1005.
3. Algarra, I., A. García-Lora, T. Cabrera, F. Ruiz-Cabello, and F. Garrido. 2004. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol. Immunother. 53:904-910.
4. Wei, X. H., and H. T. Orr. 1990. Differential expression of HLA-E, HLA-F, and HLA-G transcripts in human tissue. Hum. Immunol. 29:131-142.
5. Kovats, S., E. K. Main, C. Librach, M. Stubblebine, S. J. Fisher, and R. DeMars. 1990. A class I antigen, HLA-G, expressed in human trophoblasts. Science 248:220-223.
6. Braud, V. M., D. S. Allan, C. A. O'Callaghan, K. Söderström, A. D'Andrea, G. S. Ogg, S. Lazetic, N. T. Young, J. I. Bell, J. H. Phillips, et al. 1998. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 391:795-799.
7. Rajagopalan, S., and E. O. Long. 1999. A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J. Exp. Med. 189:1093-1100.
8. Kaiser, B. K., J. C. Pizarro, J. Kerns, and R. K. Strong. 2008. Structural basis for NKG2A/CD94 recognition of HLA-E. Proc. Natl. Acad. Sci. USA 105:6696-6701.
9. Palmisano, G. L., E. Contardi, A. Morabito, V. Gargaglione, G. B. Ferrara, and M. P. Pistillo. 2005. HLA-E surface expression is independent of the availability of HLA class I signal sequence-derived peptides in human tumor cell lines. Hum. Immunol. 66:1-12.
10. Wischhusen, J., A. Waschbisch, and H. Wiendl. 2007. Immune-refractory cancers and their little helpers-an extended role for immunetolerogenic MHC molecules HLA-G and HLA-E? Semin. Cancer Biol. 17:459-468.
11. Menier, C., N. Rouas-Freiss, B. Favier, J. LeMaoult, P. Moreau, and E. D. Carosella. 2010. Recent advances on the non-classical major histocompatibility complex class I HLA-G molecule. Tissue Antigens 75:201-206.
12. Bianchini, M., E. Levy, C. Zucchini, V. Pinski, C. Macagno, P. De Sanctis, L. Valvassori, P. Carinci, and J. Mordoh. 2006. Comparative study of gene expression by cDNA microarray in human colorectal cancer tissues and normal mucosa. Int. J. Oncol. 29:83-94.
13. Malmberg, K. J., V. Levitsky, H. Norell, C. T. de Matos, M. Carlsten, K. Schedvins, H. Rabbani, A. Moretta, K. Söderström, J. Levitskaya, and R. Kiessling. 2002. IFN-g protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. J. Clin. Invest. 110:1515-1523.
14. Marín, R., F. Ruiz-Cabello, S. Pedrinaci, R. Méndez, P. Jiménez, D. E. Geraghty, and F. Garrido. 2003. Analysis of HLA-E expression in human tumors. Immunogenetics 54:767-775. (Pubitemid 36384471)
15. Rouas-Freiss, N., P. Moreau, S. Ferrone, and E. D. Carosella. 2005. HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Cancer Res. 65:10139-10144.
16. Ye, S. R., H. Yang, K. Li, D. D. Dong, X. M. Lin, and S. M. Yie. 2007. Human leukocyte antigen G expression: as a significant prognostic indicator for patients with colorectal cancer. Mod. Pathol. 20:375-383.
17. Yie, S. M., H. Yang, S. R. Ye, K. Li, D. D. Dong, and X. M. Lin. 2007. Expression of human leukocyte antigen G (HLA-G) correlates with poor prognosis in gastric carcinoma. Ann. Surg. Oncol. 14:2721-2729.
18. Yie, S. M., H. Yang, S. R. Ye, K. Li, D. D. Dong, and X. M. Lin. 2007. Expression of HLA-G is associated with prognosis in esophageal squamous cell carcinoma. Am. J. Clin. Pathol. 128:1002-1009.
19. Yie, S. M., H. Yang, S. R. Ye, K. Li, D. D. Dong, and X. M. Lin. 2007. Expression of human leucocyte antigen G (HLA-G) is associated with prognosis in non-small cell lung cancer. Lung Cancer 58:267-274.
20. Kleinberg, L., V. A. Flørenes, M. Skrede, H. P. Dong, S. Nielsen, M. T. McMaster, J. M. Nesland, Ie M. Shih, and B. Davidson. 2006. Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma. Virchows Arch. 449:31-39.
21. Lefebvre, S., M. Antoine, S. Uzan, M. McMaster, J. Dausset, E. D. Carosella, and P. Paul. 2002. Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. J. Pathol. 196:266-274.
22. Singer, G., V. Rebmann, Y. C. Chen, H. T. Liu, S. Z. Ali, J. Reinsberg, M. T. McMaster, K. Pfeiffer, D. W. Chan, E. Wardelmann, et al. 2003. HLA-G is a potential tumor marker in malignant ascites. Clin. Cancer Res. 9:4460-4464.
23. van Nes, J. G., E. M. de Kruijf, D. Faratian, C. J. van de Velde, H. Putter, C. Falconer, V. T. Smit, C. Kay, M. J. van de Vijver, P. J. Kuppen, and J. M. Bartlett. 2010. COX2 expression in prognosis and in prediction to endocrine therapy in early breast cancer patients. Breast Cancer Res. Treat. In press.
24. Lo Monaco, E., L. Sibilio, E. Melucci, E. Tremante, M. Suchánek, V. Horejsi, A. Martayan, and P. Giacomini. 2008. HLA-E: strong association with b2-microglobulin and surface expression in the absence of HLA class I signal sequence-derived peptides. J. Immunol. 181:5442-5450.
25. Menier, C., B. Saez, V. Horejsi, S. Martinozzi, I. Krawice-Radanne, S. Bruel, C. Le Danff, M. Reboul, I. Hilgert, M. Rabreau, et al. 2003. Characterization of monoclonal antibodies recognizing HLA-G or HLA-E: new tools to analyze the expression of nonclassical HLA class I molecules. Hum. Immunol. 64:315-326.
26. Paul, P., N. Rouas-Freiss, P. Moreau, F. A. Cabestre, C. Menier, I. Khalil-Daher, C. Pangault, M. Onno, R. Fauchet, J. Martinez-Laso, et al. 2000. HLA-G,-E,-F preworkshop: tools and protocols for analysis of non-classical class I genes transcription and protein expression. Hum. Immunol. 61:1177-1195.
27. Poláková, K., D. Kuba, and G. Russ. 2004. The 4H84 monoclonal antibody detecting b2m free nonclassical HLA-G molecules also binds to free heavy chains of classical HLA class I antigens present on activated lymphocytes. Hum. Immunol. 65:157-162.
28. de Kruijf, E. M., J. G. van Nes, A. Sajet, Q. R. Tummers, H. Putter, S. Osanto, F. M. Speetjens, V. T. Smit, G. J. Liefers, C. J. van de Velde, and P. J. Kuppen. 2010. The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer. Clin. Cancer Res. 16:1272-1280.
29. Putter, H., M. Fiocco, and R. B. Geskus. 2007. Tutorial in biostatistics: competing risks and multi-state models. Stat. Med. 26:2389-2430.
30. Gonçalves, M. A., M. Le Discorde, R. T. Simões, M. Rabreau, E. G. Soares, E. A. Donadi, and E. D. Carosella. 2008. Classical and non-classical HLA molecules and p16 (INK4a) expression in precursors lesions and invasive cervical cancer. Eur. J. Obstet. Gynecol. Reprod. Biol. 141:70-74.
31. Dunn, G. P., L. J. Old, and R. D. Schreiber. 2004. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22:329-360.
32. Borrego, F., M. Ulbrecht, E. H. Weiss, J. E. Coligan, and A. G. Brooks. 1998. Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J. Exp. Med. 187:813-818.
33. Sheu, J., and IeM. Shih. 2010. HLA-G and immune evasion in cancer cells. J. Formos. Med. Assoc. 109:248-257.
34. Ishigami, S., S. Natsugoe, F. Miyazono, A. Nakajo, K. Tokuda, M. Matsumoto, H. Okumura, T. Douchi, S. Hokita, and T. Aikou. 2006. HLA-G expression in gastric cancer. Anticancer Res. 26 (3 B): 2467-2472.
35. Levy, E. M., M. Bianchini, E. M. Von Euw, M. M. Barrio, A. I. Bravo, D. Furman, E. Domenichini, C. Macagno, V. Pinsky, C. Zucchini, et al. 2008. Human leukocyte antigen-E protein is overexpressed in primary human colorectal cancer. Int. J. Oncol. 32:633-641.
36. Adrián Cabestré, F., P. Moreau, B. Riteau, E. C. Ibrahim, C. Le Danff, J. Dausset, N. Rouas-Freiss, E. D. Carosella, and P. Paul. 1999. HLA-G expression in human melanoma cells: protection from NK cytolysis. J. Reprod. Immunol. 43:183-193.
37. Münz, C., N. Holmes, A. King, Y. W. Loke, M. Colonna, H. Schild, and H. G. Rammensee. 1997. Human histocompatibility leukocyte antigen (HLA)-G molecules inhibit NKAT3 expressing natural killer cells. J. Exp. Med. 185:385-391.
38. Riteau, B., C. Menier, I. Khalil-Daher, S. Martinozzi, M. Pla, J. Dausset, E. D. Carosella, and N. Rouas-Freiss. 2001. HLA-G1 co-expression boosts the HLA class I-mediated NK lysis inhibition. Int. Immunol. 13:193-201.
39. Yu, Y., Y. Wang, and M. Feng. 2008. Human leukocyte antigen-G1 inhibits natural killer cytotoxicity through blocking the activating signal transduction pathway and formation of activating immunologic synapse. Hum. Immunol. 69:16-23.